Improving HER2 detection in breast cancer with new testing method
Part of Cancer, Skin clinical trials.
This trial studies a more precise way to measure HER2 levels in breast cancer tissue. It may help identify patients whose cancer is HER2-low or HER2-zero, so they can get more targeted treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have been diagnosed with breast cancer after January 1, 2022
- You already had surgery and chemotherapy (if needed) for your breast cancer
- You agree to let researchers look at your medical records and tissue samples
- Your cancer is either HER2-zero or HER2-low based on standard tests
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies breast cancer tumors to see how specific gene changes and DNA damage patterns relate to the cancer in people with HER2-low disease. It may help doctors better predict which patients could benefit from treatments that target these pathways.
This study looks at the genetic details of HER2-positive breast cancer to help find subtypes and improve future treatments. It does not test a new drug but collects information from your tumor tissue to learn more about the disease.
This trial tests a personalized treatment plan for HER2-positive breast cancer that has spread. It uses a blood test to track cancer DNA and adjust therapy, including treatments that may help prevent cancer from reaching the brain. The goal is to achieve long-term remission.
This trial tests different combinations of targeted therapy and chemotherapy before surgery for HER2-positive breast cancer. It uses a special PET scan to see how well the treatment is working and to help choose the best treatment plan for each person.
This trial tests two antibody-drug conjugates (Enhertu and Datroway) for breast cancer that is HER2-low or HER2-0. It aims to find the best treatment sequence for people whose cancer has stopped responding to prior therapy.
This study looks at whether some people with stage 1 HER2-positive or “triple-negative” breast cancer may safely need less (de-escalated) chemotherapy after surgery. The goal is to keep the cancer risk low while reducing treatment intensity, using special blood testing over time.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.